New pill combo aims to slow stomach cancer in Second-Line fight
NCT ID NCT07552402
First seen May 12, 2026 · Last updated Jun 12, 2026 · Updated 5 times
Summary
This study tests whether an oral chemotherapy drug (paclitaxel) plus a targeted therapy (fruquintinib) can help adults with advanced stomach or gastroesophageal junction cancer that has worsened after first-line treatment. About 150 participants will be randomly assigned to receive the new combination or the doctor's choice of standard treatment. The main goal is to see if the combination delays cancer growth or improves survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.